Clinical Trial Search

Phase 3 N=295 Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Estrogen Receptor Positive · HER2 Positive Breast Carcinoma · HER2/Neu Negative

Primary: Progression-free Survival (PFS) — 4.7; 3.8 months — p=0.37

National Cancer Institute (NCI) Results Jun 2015 9.4% serious AE View details

Phase 3 N=302 A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation

Opioid-Induced Constipation (OIC)

Primary: Incidence of Patients Experiencing at Least One Adverse Event (AE) — 32; 40; 33 Participants

AstraZeneca Results Jun 2015 5.8% serious AE View details

Phase 3 N=20 Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg

Acute Uncomplicated Falciparum Malaria

Primary: Polymerase Chain Reaction (PCR) Corrected 28 Day Parasitological Cure Rate — 16 number of participants

Novartis Pharmaceuticals Results Jun 2015 15.0% serious AE View details

Phase 3 N=86 Role of Soy Supplementation in Prostate Cancer Development

Prostate Neoplasm

Primary: Effect of Soy Isoflavones on Serum Testosterone Levels. — 376; 405 ng/ml

VA Office of Research and Development Results Jun 2015 9.3% serious AE View details

Phase 3 N=363 Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Primary: Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response — 59.2; 65.3; 23.0 percentage of participants — p=<0.001

Kythera Biopharmaceuticals Results Jun 2015 1.7% serious AE View details

Phase 3 N=506 Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

Primary: Percentage of Participants Who Achieved a Composite 1-grade Response — 70.0; 18.6 percentage of participants — p=<0.001

Kythera Biopharmaceuticals Results Jun 2015 3.6% serious AE View details

Phase 3 N=516 Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Moderate or Severe Submental Fullness

Primary: Percentage of Participants Who Achieved a Composite 1-grade Response — 66.5; 22.2 percentage of participants — p=<0.001

Kythera Biopharmaceuticals Results Jun 2015 3.3% serious AE View details

Phase 3 N=360 Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Primary: Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response — 58.3; 62.3; 34.5 percentage of participants — p=<0.001

Kythera Biopharmaceuticals Results Jun 2015 2.0% serious AE View details

Phase 3 N=900 Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine

Acute Migraine

Primary: Number of Subjects Who Are Pain Free at the 2-hour Assessment — 69; 90 participants

Novartis Results Jun 2015 0.1% serious AE View details

Phase 3 N=127 Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Anemia

Primary: Incidence of Treatment-emergent Adverse Events — 84 each event

American Regent, Inc. Results Jun 2015 18.1% serious AE View details

Phase 3 N=462 Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients

Neurotoxicity · Pain · Peripheral Neuropathy

Primary: Change in Average Daily Peripheral Neuropathy Intensity Score From Baseline to Week 6 in Patients Treated With Amitriptyline and Ketamine Hydrochloride vs Placebo…

Gary Morrow Results Jun 2015 1.8% serious AE View details

Phase 3 N=57 Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs

Ankylosing Spondylitis

Primary: the Percentage of Patients Fulfilling the Assessment Study (ASAS) Response Criteria Were Determined — 19 percentage of participants

Spanish Foundation of Rheumatology Results Jun 2015 1.8% serious AE View details

Phase 3 N=1,481 Red Cell Storage Duration Study

Cardiac Surgery · Erythrocyte Transfusion

Primary: The Change in the Composite Multiple Organ Dysfunction Score (MODS) From the Pre-operative Baseline. The Worst Post-operative Values of Each Component of MODS Will be…

Carelon Research Results Jun 2015 52.0% serious AE View details

Phase 3 N=192 Wound Infusion vs Spinal Morphine for Post-caesarean Analgesia

Post Caesarean Analgesia

Primary: Duration of Effective Analgesia — 351; 380; 247 minutes

Dr Madeleine Wilwerth Results Jun 2015 0.0% serious AE View details

Phase 3 N=1,042 A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

Chronic Obstructive Pulmonary Disease (COPD)

Primary: Change From Baseline in Standardized Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve (AUC) (0-12 Hours (h)) — 0.211; 0.117; 0.112; -0.021 Liter

Novartis Pharmaceuticals Results Jun 2015 3.8% serious AE View details